

## Annual General Meeting of the Finnish Drug Discovery Center Ltd: Jyrki Liljeroos will continue as the Chairman and Mikko Holm appointed as a new member of the Board of Directors.

On 28 March 2025, the Annual General Meeting of the Finnish Drug Discovery Center Ltd appointed the company's Board of Directors, Board Professional **Jyrki Liljeroos** continuing as the Chairman. Government Counsellor **Mikko Holm** at the Ministry of Economic Affairs and Employment, was appointed as a new member of the company's Board of Directors. He serves as the Vice Chairman of the Board. In January 2025, **Liisa Huhtala** moved from the Ministry of Economic Affairs and Employment to the position of Director General of the Private Law and Administration of Justice Department at the Ministry of Justice, and she will end her term as a member of the Board of Directors. Warm thanks to Liisa for her contribution during the company's first year of operation.

The following will continue in the Board of Directors of the Finnish Drug Discovery Center:

- **Tuula Helander**, Deputy Director General, Biotechnology and Medicines unit, Ministry of Social Affairs and Health
- **Terhi Horppu**, Chief Financial Officer, Blueprint Genetics Oy
- **Anne Portaankorva**, Vice Rector for Research and Sustainability, Professor in Neurology, University of Helsinki
- **Ilpo Tolonen**, Board Professional
- **Jukka Westermarck**, Professor, Cancer Biology, University of Turku

The Annual General Meeting of the Finnish Drug Discovery Center Ltd appoints a Board of Directors whose duties include supervising the implementation of the company's strategy and being responsible for the productivity and appropriate organisation of operational activities.

The Finnish Drug Discovery Center is a limited liability company wholly owned by the State of Finland, with the Ministry of Economic Affairs and Employment acting as its ownership steerer. The company's special assignment is to promote competitive drug development and commercial success of Finland in this sector. The company fulfils its special assignment by identifying and evaluating promising drug candidates and guiding the planning of the early development phases of the drug candidates selected in the company's portfolio. The company also aims to build channels for international financing and commercial success by expanding cooperation networks in drug development supply chains and with key stakeholders. The activities focus on Finnish pharmaceutical innovations and the establishment and development of start-ups in Finland. The company's mission is to be a valued partner of the research community in developing innovative drug compounds on their path to international success.

### More info:

Chairman of the Board Jyrki Liljeroos  
[jyrki.liljeroos@laakekehityskeskus.fi](mailto:jyrki.liljeroos@laakekehityskeskus.fi)